Aktienanalyse zu SeaStar Medical Holding Corp (ICU)ICUSeaStar Medical Holding Corp

SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA). It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, SeaStar Medical Holding Corp (ICU) is not a good buy. The stock is trading at $1.89, which is significantly below its 52-week high of $5.38, indicating a decline of approximately 65%. Additionally, the stock has a very low RSI of 17.358, suggesting it is oversold, but this could also indicate continued downward pressure. The forward P/E ratio is 0, and the company has reported consistent net losses, with a net income of -3,730,000 USD in Q2 2026. The main risk is the company's ongoing financial struggles, as evidenced by a 60.62% decline in stock price over the past year and a 15.63% drop in the last five days, which raises concerns about its viability in the long term.